ERBB2 and breast carcinoma: In breast cancer, HER-2/neu amplification or overexpression, according to standardised criteria, has been described as a marker predicting both response to treatment and poor prognosis with nodal metastases (Slamon et al, 1987; Menard et al, 2000; Yamauchi et al, 2001).